China SXT Pharmaceuticals, Inc. (SXTC) Revenue History
Annual and quarterly revenue from 2016 to present
SXTC Revenue Over Time (2016–2025)
SXTC Revenue Growth History
2 of 9 years with positive growth- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- +31.3%
- FY2018 revenue growth
- +43.8%
- FY2019 revenue growth
- -0.1%
- FY2020 revenue growth
- -26.4%
- FY2021 revenue growth
- -7.5%
- FY2022 revenue growth
- -45.5%
- FY2023 revenue growth
- -24.2%
- FY2024 revenue growth
- -2.2%
- FY2025 revenue growth
- -9.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $456K | -7.8% |
| Q3 2025 | $456K | -7.8% |
| Q2 2025 | $415K | -55.9% |
| Q1 2025 | $415K | -11.7% |
| Q4 2024 | $494K | -35.2% |
| Q3 2024 | $494K | +29.5% |
| Q2 2024 | $940K | -22.2% |
| Q1 2024 | $470K | -22.2% |
Multi-year avg. share of annual revenue by fiscal quarter
SXTC Revenue Analysis (2016–2025)
Current Revenue & Growth
As of June 22, 2026, China SXT Pharmaceuticals, Inc. (SXTC) generated trailing twelve-month (TTM) revenue of $1.7 million, reflecting moderate decline in growth of -7.8% year-over-year. The most recent quarter (Q4 2025) recorded $455,709 in revenue, up 0.0% sequentially.
Historical Growth Trajectory
SXTC's 5-year compound annual growth rate (CAGR) stands at -19.5%, indicating revenue contraction over this period. The 3-year CAGR of -12.5% exceeds the 5-year average, indicating an acceleration in the most recent period. China SXT Pharmaceuticals, Inc.'s highest annual revenue of $7.0 million was recorded in 2018.
Peer Comparison
Compared to Healthcare sector peers — including SBFM (-2.0% YoY), TCMD (+17.2% YoY), and CODA (+22.8% YoY) — SXTC has underperformed the peer group in revenue growth. Compare SXTC vs SBFM →
SXTC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SXTCCurrent | $2M | -7.8% | -19.5% | -154.0% | |
 SBFM | $36M | -2.0% | +247.7% | -12.3% | |
 TCMD | $330M | +17.2% | +12.0% | 8.9% | |
 CODA | $27M | +22.8% | +5.8% | 17.1% | |
 CCRN | $1.1B | -20.4% | +4.7% | -0.3% |
SXTC Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.7M | -9.7% | $367K | 21.1% | $-2,680,479 | -154.0% |
| 2024 | $1.9M | -2.2% | $554K | 28.7% | $-2,515,217 | -130.4% |
| 2023 | $2.0M | -24.2% | $426K | 21.6% | $-5,607,509 | -284.4% |
| 2022 | $2.6M | -45.5% | $1.3M | 48.1% | $-5,189,673 | -199.4% |
| 2021 | $4.8M | -7.5% | $2.8M | 59.4% | $-2,197,076 | -46.0% |
| 2020 | $5.2M | -26.4% | $2.7M | 52.4% | $4.3M | 83.0% |
| 2019 | $7.0M | -0.1% | $4.6M | 65.8% | $1.8M | 25.2% |
| 2018 | $7.0M | +43.8% | $3.4M | 48.5% | $1.6M | 23.3% |
| 2017 | $4.9M | +31.3% | $2.3M | 47.4% | $1.6M | 32.8% |
| 2016 | $3.7M | - | $794K | 21.4% | $209K | 5.6% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SXTC — Frequently Asked Questions
Quick answers to the most common questions about buying SXTC stock.
Is SXTC's revenue growth accelerating or slowing?
SXTC revenue is declining -7.8% year-over-year. TTM revenue fell to $2M, contrasting with the 5-year CAGR of -19.5%. The reversal reflects either macro headwinds or company-specific challenges.
What is SXTC's revenue history from 2016 to 2026?
China SXT Pharmaceuticals, Inc. (SXTC) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $2M, growing at -7.8% YoY. The 5-year CAGR is -19.5%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SXTC's long-term revenue growth rate (CAGR)?
China SXT Pharmaceuticals, Inc.'s 5-year revenue CAGR of -19.5% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -7.8% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SXTC.
Why does SXTC's quarterly revenue fluctuate?
SXTC quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. China SXT Pharmaceuticals, Inc.'s revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is SXTC's revenue distributed by segment?
SXTC reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SXTC's revenue compare to industry peers?
China SXT Pharmaceuticals, Inc. (SXTC) with TTM revenue of $2M and -7.8% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.